| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 369 | 394 | 445 | 472 | 429 | 481 | 523 | 552 | 483 | 478 | 550 | 602 | 536 | 519 | 559 | 490 | 517 | 620 | 656 | 666 | 739 | 681 | 721 | 754 | 759 | 781 | 914 | 862 | 900 | 984 | 978 | 1,007 | 919 | 1,053 | 1,050 | 1,119 | 1,090 | 1,171 | 1,206 | 1,177 |
| Expenses | 248 | 269 | 288 | 313 | 289 | 310 | 343 | 356 | 319 | 346 | 357 | 390 | 391 | 354 | 378 | 378 | 388 | 444 | 466 | 466 | 533 | 445 | 442 | 507 | 497 | 528 | 622 | 598 | 664 | 729 | 742 | 802 | 733 | 750 | 738 | 791 | 776 | 815 | 876 | 825 |
| EBITDA | 121 | 125 | 157 | 159 | 140 | 171 | 179 | 197 | 163 | 132 | 193 | 213 | 145 | 166 | 182 | 112 | 129 | 176 | 190 | 200 | 206 | 236 | 279 | 247 | 262 | 253 | 292 | 264 | 236 | 255 | 237 | 205 | 186 | 303 | 312 | 328 | 314 | 357 | 331 | 351 |
| Operating Profit % | 32 % | 30 % | 34 % | 33 % | 32 % | 35 % | 33 % | 33 % | 33 % | 27 % | 34 % | 34 % | 26 % | 31 % | 31 % | 22 % | 25 % | 28 % | 27 % | 29 % | 22 % | 33 % | 38 % | 32 % | 34 % | 29 % | 30 % | 29 % | 24 % | 23 % | 21 % | 17 % | 17 % | 27 % | 28 % | 28 % | 26 % | 29 % | 26 % | 28 % |
| Depreciation | 13 | 10 | 11 | 12 | 11 | 13 | 14 | 15 | 19 | 13 | 15 | 15 | 17 | 17 | 18 | 19 | 19 | 23 | 23 | 24 | 26 | 28 | 28 | 29 | 31 | 31 | 32 | 32 | 31 | 32 | 33 | 33 | 33 | 33 | 34 | 34 | 34 | 34 | 34 | 36 |
| Interest | 2 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 5 | 2 | 4 | 2 | 2 | 3 | 3 | 2 | 0 | 1 | 7 | 1 | 1 | 3 | 1 | 1 | 2 | 3 | 2 | 1 | 6 | 8 |
| Profit Before Tax | 115 | 119 | 148 | 153 | 134 | 158 | 165 | 181 | 144 | 119 | 178 | 198 | 128 | 148 | 164 | 93 | 109 | 151 | 162 | 175 | 176 | 207 | 249 | 216 | 229 | 220 | 260 | 231 | 198 | 222 | 203 | 168 | 152 | 269 | 276 | 291 | 278 | 322 | 290 | 307 |
| Tax | 41 | 33 | 45 | 39 | 25 | 39 | 35 | 38 | 30 | 24 | 46 | 50 | 34 | 43 | 38 | 26 | 20 | 37 | 45 | 68 | 47 | 59 | 79 | 39 | 70 | 47 | 65 | 39 | 47 | 47 | 46 | 34 | 30 | 61 | 81 | 81 | 75 | 76 | 74 | 75 |
| Net Profit | 74 | 86 | 103 | 114 | 109 | 120 | 131 | 143 | 114 | 95 | 132 | 148 | 95 | 106 | 125 | 67 | 89 | 115 | 116 | 108 | 129 | 148 | 170 | 177 | 159 | 174 | 196 | 192 | 151 | 175 | 157 | 135 | 122 | 208 | 195 | 210 | 203 | 246 | 217 | 233 |
| EPS in ₹ | 8.43 | 9.78 | 11.76 | 12.95 | 12.38 | 13.58 | 14.85 | 16.19 | 12.96 | 10.77 | 14.99 | 16.76 | 10.74 | 12.02 | 14.25 | 7.60 | 10.10 | 13.14 | 13.34 | 12.33 | 14.80 | 16.93 | 19.51 | 20.41 | 18.40 | 20.08 | 15.10 | 22.16 | 17.70 | 13.63 | 12.22 | 10.50 | 9.54 | 16.53 | 15.51 | 16.68 | 16.10 | 19.54 | 17.27 | 18.60 |
Ajanta Pharma
2,774.30
+6.35
(0.23%)
There are new updates from the company1 day ago
View
Market Cap
3,283.30 Cr
EPS
64.82
PE Ratio
38.55
Dividend Yield
1.86 %
Industry
Healthcare52 Week High
3,485.00
52 Week Low
2,051.60
PB Ratio
9.41
Debt to Equity
0.01
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from8 analysts
Company News
View All News
Ajanta Pharma Added to FTSE All World Index4 days ago
Ajanta Pharma has been added to the FTSE All World Index, which is expected to result in an inflow of approximately $23.8 million (2.0 billion rupees) into the stock.
Ajanta Pharma Announces Expansion of Pithampur Facility5 days ago
Ajanta Pharma has announced plans to expand its manufacturing capabilities by adding a liquid formulation facility at its Pithampur site. The company states that this expansion will require an investment of 920 million rupees.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,764.75 | 4,28,233.30 | 35.92 | 49,887.20 | 12.06 | 9,648 | 13.77 | 61.58 | |
| 5,840.65 | 1,56,910.50 | 74.97 | 8,184.00 | 0.89 | 1,600 | 64.53 | 55.23 | |
| 1,511.20 | 1,23,084.40 | 24.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 60.28 | |
| 3,245.05 | 1,10,720.70 | 58.75 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.68 | |
| 1,177.90 | 1,00,988.70 | 18.34 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.86 | |
| 2,398.05 | 97,867.10 | 48.47 | 10,615.60 | 19.57 | 1,942 | -16.38 | 56.07 | |
| 2,068.75 | 96,711.60 | 32.93 | 20,141.50 | 19.94 | 1,936 | 38.82 | 54.50 | |
| 907.35 | 92,945.80 | 20.14 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.54 | |
| 1,194.95 | 70,253.80 | 19.68 | 29,559.20 | 17.55 | 3,169 | -10.04 | 61.05 | |
| 31,101.85 | 66,026.50 | 49.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 61.04 |
Growth Rate
Revenue Growth
11.77 %
Net Income Growth
38.81 %
Cash Flow Change
-0.89 %
ROE
31.87 %
ROCE
41.19 %
EBITDA Margin (Avg.)
27.48 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,146 | 1,481 | 1,848 | 2,449 | 2,696 | 3,319 | 3,779 | 4,056 | 4,679 | 4,638 |
| Fixed Assets | 288 | 452 | 589 | 1,053 | 1,178 | 1,472 | 1,541 | 1,512 | 1,496 | 1,479 |
| Current Assets | 633 | 764 | 851 | 1,224 | 1,180 | 1,642 | 2,028 | 2,265 | 2,834 | 2,731 |
| Capital Work in Progress | 170 | 240 | 339 | 61 | 262 | 132 | 108 | 153 | 210 | 257 |
| Investments | 20 | 66 | 182 | 190 | 78 | 79 | 176 | 147 | 535 | 349 |
| Other Assets | 669 | 724 | 738 | 1,145 | 1,179 | 1,635 | 1,954 | 2,244 | 2,438 | 2,554 |
| Total Liabilities | 1,146 | 1,481 | 1,848 | 2,449 | 2,696 | 3,319 | 3,779 | 4,056 | 4,679 | 4,638 |
| Current Liabilities | 250 | 272 | 247 | 346 | 378 | 606 | 649 | 647 | 1,139 | 896 |
| Non Current Liabilities | 56 | 38 | 33 | 61 | 73 | 114 | 135 | 144 | 152 | 175 |
| Total Equity | 841 | 1,172 | 1,568 | 2,041 | 2,245 | 2,599 | 2,996 | 3,264 | 3,388 | 3,567 |
| Reserve & Surplus | 823 | 1,154 | 1,550 | 2,024 | 2,228 | 2,581 | 2,978 | 3,247 | 3,363 | 3,542 |
| Share Capital | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 25 | 25 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 16 | -0 | 24 | 25 | 4 | 104 | -24 | 28 | 124 | -201 |
| Investing Activities | -158 | -209 | -383 | -256 | -223 | -224 | -282 | -74 | -560 | 65 |
| Operating Activities | 279 | 326 | 609 | 281 | 375 | 457 | 576 | 562 | 792 | 785 |
| Financing Activities | -105 | -117 | -202 | -0 | -148 | -129 | -318 | -460 | -108 | -1,051 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Apr 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 70.34 % | 70.34 % | 70.34 % | 70.34 % | 70.48 % | 70.48 % | 70.48 % | 66.11 % | 66.11 % | 66.21 % | 66.21 % | 66.21 % | 66.21 % | 66.21 % | 66.27 % | 66.26 % | 66.26 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 8.54 % | 8.36 % | 9.11 % | 9.26 % |
| DIIs | 10.88 % | 11.04 % | 11.51 % | 11.55 % | 11.61 % | 11.92 % | 12.15 % | 15.82 % | 15.98 % | 16.02 % | 14.70 % | 14.91 % | 16.01 % | 17.49 % | 17.41 % | 17.10 % | 17.02 % |
| Government | 0.76 % | 0.43 % | 0.43 % | 0.45 % | 0.45 % | 0.45 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 7.64 % | 7.42 % | 7.45 % | 7.29 % | 7.33 % | 7.45 % | 7.31 % | 7.17 % | 7.10 % | 6.94 % | 6.92 % | 7.21 % | 7.07 % | 6.91 % | 7.08 % | 6.71 % | 6.67 % |
| Others | 10.37 % | 10.76 % | 10.26 % | 10.37 % | 10.13 % | 9.70 % | 10.06 % | 10.90 % | 10.82 % | 10.82 % | 12.16 % | 11.67 % | 10.70 % | 0.84 % | 0.86 % | 0.80 % | 0.79 % |
| No of Share Holders | 44,881 | 45,664 | 52,263 | 57,897 | 60,759 | 64,445 | 62,048 | 59,798 | 83,549 | 56,939 | 54,874 | 56,277 | 54,351 | 55,488 | 70,316 | 64,315 | 66,896 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 8 | 13 | 0.00 | 9 | 13 | 9.5 | 9.5 | 7 | 51 | 0.00 |
| Dividend Yield (%) | 0.68 | 1.4 | 0.00 | 0.99 | 1.09 | 0.79 | 0.79 | 0.31 | 1.84 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
Intimation For Capacity Addition Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
Participation In Investor Conference
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
Participation In Investor Conference
Integrated Filing (Financial)
Grant Of Stock Appreciation Rights
Rumour verification - Regulation 30(11)
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Cancellation Of Employee Stock Options
Board Meeting Outcome for Outcome Of Board Meeting For Approving Unaudited Financial Results For The Quarter And Nine Months Ended 31St December 2024 Pursuant To Reg 33 Of SEBI (LODR)
Unaudited (Consolidated & Standalone) Financial Results For The Quarter And Nine Months Ended 31St December 2024.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Approving Unaudited Financial Results For The Quarter Ended 31St December 2024.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
Closure of Trading Window
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Corporate Action- Fixation Of Record Date For Ist Interim Dividend For FY 25.
Corporate Action-Board approves Dividend
Unaudited (Consolidated & Standalone) Financial Results For The Quarter And Half Year Ended 30.09.2024.
Board Meeting Outcome for Outcome Of Board Meeting For Approving Unaudited Financial Results For Quarter And Half Year Ended 30.09.2024
Intimation Of Record Date For The Purpose Of Dividend
Corporate Action-Board to consider Dividend
Update On Board Meeting
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Board Meeting Scheduled To Be Held On Monday 28Th October 2024.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Participation In Investor Conference
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Participation In Investor Conference
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Technical Indicators
RSI(14)
Neutral 62.76
ATR(14)
Less Volatile 118.41
STOCH(9,6)
Neutral 78.96
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 34.45
ADX(14)
Weak Trend 24.63
UO(9)
Bearish 52.73
ROC(12)
Uptrend But Slowing Down 7.97
WillR(14)
Neutral -23.76
About Ajanta Pharma
Ajanta Pharma is an Indian specialty pharmaceutical company focusing on branded generic products. It operates in India, Asia, Africa, and the USA, offering a range of therapeutic products including cardiology, dermatology, ophthalmology, and pain management. The company has seven manufacturing facilities in India and Mauritius, with two approved by the US FDA. Ajanta Pharma has a strong research and development center in Mumbai with over 750 scientists. The company's business includes branded generics in emerging markets, generics in the USA, and institutional sales. Established in 1973, Ajanta Pharma has expanded its operations over the years, entering new markets and launching various products. The company is publicly listed on the BSE and NSE, and has undertaken several expansion projects and buybacks in recent years.
Listing Date
05 Jun, 2000(24 Years,
49 days)
Website
Chairperson NameMannalal B Agrawal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
